A spokesperson for BioNTech confirmed to Reuters earlier on Thursday, when asked to comment on the stake sale, that its collaboration with Pfizer has not changed.
Their relationship intensified in early 2020 as the COVID pandemic unfolded, when the two companies joined forces to create the world's first authorized mRNA vaccine for the respiratory disease. The vaccine, marketed as Comirnaty, generated annual sales of $37.8 billion at its peak in 2022.
The tie-up resulted in Pfizer gaining access to an unprecedented influx of cash to indulge in a deal-making spree, including the $43 billion buyout of cancer drug specialist Seagen, sickle cell disease drugmaker Global Blood Therapeutics, and pain management drugmaker Biohaven.
Pfizer is now focusing on revving up its pipeline as CEO Albert Bourla sets his sights on an extra $20 billion in revenue by 2030 and a looming patent cliff for some of its best-selling drugs.
The drugmaker has also closed its up to $10 billion acquisition of Metsera earlier in the day, gaining a foothold in the fast-growing obesity market.
Meanwhile, following the pandemic BioNTech shifted its focus to different areas of research, such as cancer, using the cash it acquired to fund research.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.